Life Saving Innovation in Neurodegenerative Disease Treatment: An Interview with Alon Ben-Noon, CEO & Founder of NeuroSense Therapeutics

NeuroSense Therapeutics, led by CEO and founder Alon Ben-Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter with an ALS advocate, Ben-Noon assembled a team of top scientists to develop PrimeC; a promising drug designed to extend lifespan and enhance quality of life for patients.

In this exclusive interview with TechBullion, Ben-Noon shares insights into NeuroSense’s pioneering strategy, the challenges of neurodegenerative drug development, and the promising future of treatments like PrimeC. With regulatory momentum and an expanding pipeline targeting Alzheimer’s and Parkinson’s, NeuroSense is charting a transformative path in neurological care.

Please tell us more about yourself.

My name is Alon Ben-Noon, founder and CEO of NeuroSense Therapeutics. My lifelong mission is to develop the most effective treatment for ALS, aiming to improve patients’ quality of life and extend their life expectancy.

What is NeuroSense and  what problems are you solving?

NeuroSense is a biotechnology company dedicated to developing innovative therapies for ALS and other neurological disorders, with the goal of improving patients’ quality of life, extending lifespan, and alleviating the burden on both patients and their families.

NeuroSense Therapeutics was founded with a mission to develop innovative treatments for neurodegenerative diseases. What inspired you to create the company, and how has your strategy evolved over time?

NeuroSense Therapeutics was founded in 2017 by Alon Ben-Noon, inspired by a chance encounter with Shay Rishoni, an ALS advocate and patient. Driven by the urgent need for better treatments, Alon assembled a team of top scientists and biotech experts to develop innovative therapies for neurodegenerative diseases.

NeuroSense takes a multi-targeted approach, combining cutting-edge science and deep clinical expertise to tackle ALS and other conditions. Our lead drug candidate, PrimeC, is designed to improve patients’ quality of life and extend lifespan. With a fast-moving team and strategic global vision, we are committed to delivering life-changing therapies efficiently and effectively.

PrimeC, your lead drug candidate for ALS, has shown promise in clinical trials. What makes this treatment unique, and what are the next critical milestones for its development?

PrimeC stands out due to its multi-targeted approach and unique formulation, which optimizes the synergy between its combined molecules. This innovative design allows PrimeC to address multiple key disease mechanisms simultaneously, contributing to the meaningful clinical benefits observed in ALS patients.

Looking ahead, our next critical milestones include advancing our Phase 3 clinical trial, securing regulatory approvals, and working closely with key stakeholders to accelerate the path to market. Our goal is to bring PrimeC to ALS patients as quickly and efficiently as possible.

NeuroSense has received Orphan Drug Designation for PrimeC from both the FDA and EMA. How does this status accelerate the drug development process, and what advantages does it provide in terms of market access?

Orphan Drug Designation (ODD) from both the FDA and EMA provides significant advantages that accelerate PrimeC’s development and market access. This designation is granted to promising treatments for rare diseases like ALS, where there is a critical unmet need.

Key benefits include:

• Regulatory Support & Faster Development – Access to guidance from regulatory agencies, facilitating a smoother and more efficient approval process.

• Financial Incentives – Eligibility for fee reductions, tax credits, and potential grant funding to support clinical development.

• Market Exclusivity – Seven years (U.S.) and ten years (EU) of market exclusivity post-approval, limiting competition and ensuring a strong commercial pathway.

• Expedited Review Processes – Potential for priority regulatory review, accelerating the time it takes to bring PrimeC to ALS patients.

With Orphan Drug Designation, NeuroSense is positioned to advance PrimeC efficiently, maximizing its potential to improve patient outcomes while navigating a faster and more sustainable regulatory pathway.

NeuroSense is expanding its focus to other neurodegenerative diseases like Alzheimer’s and Parkinson’s. Can you share insights into these pipeline programs and how your research in ALS translates into these areas?

NeuroSense’s multi-targeted approach, which has shown promise in ALS, is now being applied to other neurodegenerative diseases, including Alzheimer’s and Parkinson’s. These diseases share common pathological mechanisms, such as neuroinflammation, oxidative stress, and impaired protein clearance, making our research highly translatable across indications.

Our pipeline expansion is driven by:

1) Strong Scientific Foundation – The insights gained from ALS research allow us to strategically adapt our approach to address similar disease mechanisms in Alzheimer’s and Parkinson’s.

2) Optimized Drug Combinations – By leveraging our expertise in multi-drug formulations, we aim to enhance efficacy and slow disease progression in these conditions.

3) Robust Preclinical and Clinical Strategy – We are evaluating PrimeC and other novel combinations in models of Alzheimer’s and Parkinson’s, with the goal of advancing them into clinical development.

By expanding our focus, NeuroSense is committed to delivering life-changing therapies to a broader patient population, accelerating innovation across neurodegenerative diseases.

NeuroSense follows a multi-targeted therapeutic approach in treating neurodegenerative diseases. Can you explain how this differs from traditional drug development methods and why it could be more effective?

NeuroSense’s multi-targeted therapeutic approach differs from traditional drug development by addressing multiple key disease mechanisms simultaneously, rather than focusing on a single target.

How It Differs from Traditional Methods:

•  Traditional Approach – Most neurodegenerative disease treatments target one specific pathway, which often leads to limited efficacy due to the complex nature of these diseases.

• NeuroSense’s Multi-Targeted Approach – We combine synergistic molecules that work together to tackle multiple underlying mechanisms, such as neuroinflammation, oxidative stress, and impaired protein clearance—all major contributors to diseases like ALS, Alzheimer’s, and Parkinson’s.

Why It Could Be More Effective:

1) Maximizes Therapeutic Impact – By targeting multiple disease pathways, our approach has the potential to slow disease progression more effectively.

2) Reduces Treatment Resistance – Neurodegenerative diseases are complex and adaptive; a multi-targeted strategy lowers the risk of disease escape mechanisms that limit single-drug effectiveness.

3) Enhances Patient Outcomes – Our lead candidate, PrimeC, has shown promising clinical benefits in ALS, demonstrating the potential of this approach to improve quality of life and extend lifespan.

By integrating cutting-edge research and novel drug combinations, NeuroSense aims to redefine treatment strategies and deliver more impactful therapies for patients with neurodegenerative diseases.

The complexity of ALS and similar conditions has made drug discovery challenging. What are some of the biggest scientific hurdles in developing effective neurodegenerative treatments, and how is NeuroSense addressing them?

Developing effective treatments for ALS and other neurodegenerative diseases presents major scientific challenges due to the complexity, variability, and progressive nature of these conditions.

Key Scientific Hurdles:

• Multifactorial Disease Mechanisms – ALS involves neuroinflammation, oxidative stress, mitochondrial dysfunction, and impaired protein clearance, making it difficult to target with a single therapy.

• Lack of Biomarkers – Identifying reliable biomarkers for early diagnosis and treatment response remains a challenge, slowing drug development.

• Blood-Brain Barrier (BBB) – Many potential treatments struggle to effectively reach the brain and spinal cord, limiting their impact.

• Heterogeneity Among Patients – ALS progresses differently in each patient, making it difficult to design one-size-fits-all treatments.

How NeuroSense is Addressing These Challenges:

1) Multi-Targeted Approach – Instead of focusing on a single pathway, PrimeC is designed to synergistically target multiple key disease mechanisms, enhancing its therapeutic effect.

2) Biomarker-Driven Research – We are actively identifying biomarkers to track disease progression and optimize treatment strategies.

3) Advanced Drug Formulation – PrimeC’s unique formulation improves drug delivery across the BBB, ensuring higher bioavailability in the central nervous system.

The neurodegenerative disease market is becoming increasingly competitive. How does NeuroSense differentiate itself in terms of innovation, clinical strategy, and commercial potential?

NeuroSense stands out in the highly competitive neurodegenerative disease market through its innovative multi-targeted approach, strategic clinical development, and strong commercial potential.

Key Differentiators:

1) Breakthrough Multi-Targeted Approach – Unlike traditional single-target drugs, PrimeC is designed to synergistically address multiple key disease mechanisms, such as neuroinflammation, oxidative stress, and impaired protein clearance—a strategy that has shown clinical promise in ALS.

2) Robust Clinical Strategy – NeuroSense’s data-driven and biomarker-supported approach enables us to optimize trial design, improve patient selection, and enhance regulatory pathways, ensuring efficient clinical advancement. Our lead candidate, PrimeC, is progressing through late-stage clinical trials, setting a clear path toward regulatory approval.

3) Global Vision, Patient-Centric Focus – We work closely with leading scientists, key opinion leaders, and patient advocacy groups to ensure our treatments directly address patient needs, maximizing real-world impact.

By combining scientific innovation, strategic execution, and a strong regulatory pathway, NeuroSense is well-positioned to bring transformative therapies to market and make a lasting impact in neurodegenerative disease treatment.

With growing investments and attention on neurodegenerative disease treatments, how do you see the biotech industry evolving in the next five to ten years?

The biotech industry is undergoing a transformative shift in the neurodegenerative disease space, driven by growing investments, scientific advancements, and a deeper understanding of disease mechanisms. Over the next 5 to 10 years, we expect significant breakthroughs in drug development, precision medicine, and patient care.

Key Trends Shaping the Future:

1) Rise of Multi-Targeted and Combination Therapies – Given the complexity of diseases like ALS, Alzheimer’s, and Parkinson’s, the industry is moving away from single-target drugs toward multi-modal approaches that tackle multiple disease pathways simultaneously.

2) Biomarker-Driven Precision Medicine – Advances in genomics, AI, and biomarker research will allow for better patient stratification, earlier diagnosis, and personalized treatment approaches, leading to higher success rates in clinical trials.

3) Expanded Regulatory Support & Fast-Tracking Programs – Agencies like the FDA and EMA are increasingly providing expedited pathways, orphan drug incentives, and adaptive trial designs to accelerate drug approval for high-need conditions.

4) Convergence of AI, Big Data & Drug Discovery – Machine learning and AI-driven drug discovery will dramatically reduce development timelines and improve target identification, leading to faster and more cost-effective breakthroughs.

For more information, visit the website: https://www.neurosense-tx.com/